Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
  • Challenge: Minimising immuno-oncology toxicity

Checkpoint inhibitor, T-cell redirector efficacy and irAEs are characterised by T-cell clonal expansion. Oxford researchers are investigating T cell specificity in treated patients to identify on-target and off-cancer reactivities. This knowledge can be used to modify clinical decision making and facilitate vaccine candidature with minimal on target off cancer effects. Similar approaches will underpin pioneering work in stem cell transplantation treatment of myeloid leukaemia by identifying T-cell Receptors that recognise Graft vs Leukemia but not Graft vs Host Disease epitopes with a view to developing epitope-driven pre-transplant conditioning regimes.